{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:13Z","timestamp":1791352213769,"version":"4.3.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.beem.2016.05.004","type":"journal-article","created":{"date-parts":[[2016,5,29]],"date-time":"2016-05-29T03:14:32Z","timestamp":1464491672000},"page":"431-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Managing dyslipidaemia in type 2 diabetes mellitus"],"prefix":"10.1016","volume":"30","author":[{"given":"Auryan","family":"Szalat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Durst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Leitersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2016.05.004_bib1","first-page":"837","article-title":"UK prospective diabetes study (UKPDS) group","volume":"352","author":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2016.05.004_bib2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib3","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib4","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib5","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.beem.2016.05.004_bib7","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.2337\/dcS13-2018","article-title":"Is glucose control important for prevention of cardiovascular disease in diabetes?","volume":"36","author":"Mannucci","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.05.004_bib8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/0002-8703(85)90224-8","article-title":"Lipids, diabetes, and coronary heart disease: insights from the Framingham study","volume":"110","author":"Kannel","year":"1985","journal-title":"Am Heart J"},{"key":"10.1016\/j.beem.2016.05.004_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.diabres.2005.03.032","article-title":"Prevalence and control of dyslipidaemia among persons with diabetes in the United States","volume":"70","author":"Jacobs","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.beem.2016.05.004_bib10","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/diacare.20.11.1683","article-title":"Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex","volume":"20","author":"U.K. Prospective Diabetes Study 27","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.05.004_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidaemia in type 2 diabetes","volume":"239","author":"Taskinen","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2016.05.004_bib12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.amjcard.2012.04.046","article-title":"Evaluation of low-density lipoprotein particle number distribution in patients with type 2 diabetes mellitus with low-density lipoprotein cholesterol <50 mg\/dl and non-high-density lipoprotein cholesterol <80 mg\/dl","volume":"110","author":"Malave","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.beem.2016.05.004_bib13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2016.05.004_bib14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/01.CIR.103.15.1949","article-title":"Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study","volume":"103","author":"Sirtori","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2016.05.004_bib15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2016.05.004_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4279","article-title":"HDL-targeted therapies: progress, failures and future","volume":"13","author":"Kingwell","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.beem.2016.05.004_bib17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2016.05.004_bib18","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.ATV.20.3.830","article-title":"LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the strong heart study","volume":"20","author":"Howard","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2016.05.004_bib19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2016.05.004_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10238-007-0121-3","article-title":"Association between glycaemic control and serum lipids profile in type 2 diabetic patients: HbA1c predicts dyslipidaemia","volume":"7","author":"Khan","year":"2007","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.beem.2016.05.004_bib21","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.2337\/dc09-0256","article-title":"Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes","volume":"32","author":"Gatti","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.05.004_bib22","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidaemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2016.05.004_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2005.12.026","article-title":"Lipid and lipoprotein dysregulation in insulin resistant states","volume":"368","author":"Avramoglu","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.beem.2016.05.004_bib24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MOL.0000000000000067","article-title":"The composition and metabolism of large and small LDL","volume":"25","author":"Diffenderfer","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.beem.2016.05.004_bib25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cmet.2012.04.001","article-title":"Inflammation and lipid signaling in the etiology of insulin resistance","volume":"15","author":"Glass","year":"2012","journal-title":"Cell Metab"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2016.05.004_bib26","first-page":"S1","article-title":"Standards of medical care in diabetes\u20132015","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.05.004_bib27","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"Ryden","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2016.05.004_bib28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","article-title":"Update on prevention of cardiovascular disease in adults with Type 2 Diabetes Mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American diabetes association","volume":"132","author":"Fox","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2016.05.004_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2010.09.023","article-title":"Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial","volume":"161","author":"Gepner","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.beem.2016.05.004_bib30","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.2013.1644","article-title":"Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes","volume":"309","author":"Clair","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2016.05.004_bib31","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.puhe.2007.02.014","article-title":"Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials","volume":"121","author":"Kelley","year":"2007","journal-title":"Public Health"},{"key":"10.1016\/j.beem.2016.05.004_bib32","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.2337\/dc10-1881","article-title":"Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis","volume":"34","author":"Chudyk","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.05.004_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.diabres.2012.10.004","article-title":"Effects of supervised exercise on lipid profiles and blood pressure control in people with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"98","author":"Hayashino","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.beem.2016.05.004_bib34","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00125-014-3303-z","article-title":"Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"57","author":"Schwingshackl","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.beem.2016.05.004_bib35","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.2337\/dc10-1548","article-title":"Exercise and type 2 diabetes: the American College of Sports Medicine and the American diabetes association: joint position statement executive summary","volume":"33","author":"Colberg","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.05.004_bib36","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/dc11-2216","article-title":"Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010","volume":"35","author":"Wheeler","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.05.004_bib37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3945\/ajcn.112.042457","article-title":"Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes","volume":"97","author":"Ajala","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.beem.2016.05.004_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycaemia","volume":"367","author":"Bosch","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.beem.2016.05.004_bib39","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.2337\/dc14-S120","article-title":"Nutrition therapy recommendations for the management of adults with diabetes","volume":"37","author":"Evert","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.beem.2016.05.004_bib40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/M14-1650","article-title":"Effects of initiating moderate alcohol intake on cardiometabolic risk in adults with Type 2 diabetes: a 2-year randomized, controlled trial","volume":"163","author":"Gepner","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2016.05.004_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.numecd.2012.06.002","article-title":"Low glycaemic index diets and blood lipids: a systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Goff","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.beem.2016.05.004_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fpubh.2015.00069","article-title":"Effect of mediterranean diet in diabetes control and cardiovascular risk modification: a systematic review","volume":"3","author":"Sleiman","year":"2015","journal-title":"Front Public Health"},{"key":"10.1016\/j.beem.2016.05.004_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1741-7015-9-74","article-title":"Efficacy of aerobic exercise and a prudent diet for improving selected lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials","volume":"9","author":"Kelley","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.beem.2016.05.004_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1467-789X.2008.00547.x","article-title":"Long-term effectiveness of diet-plus-exercise interventions vs. diet-only interventions for weight loss: a meta-analysis","volume":"10","author":"Wu","year":"2009","journal-title":"Obes Rev"},{"key":"10.1016\/j.beem.2016.05.004_bib45","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","article-title":"Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial","volume":"30","author":"Pi-Sunyer","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.05.004_bib46","first-page":"1566","article-title":"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the look AHEAD trial","volume":"170","author":"Wing","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beem.2016.05.004_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.beem.2016.05.004_bib48","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.beem.2016.05.004_bib49","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.metabol.2014.10.018","article-title":"Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis","volume":"64","author":"Chen","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2016.05.004_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.7326\/0003-4819-159-8-201310150-00007","article-title":"Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Schellenberg","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2016.05.004_bib51","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2016.05.004_bib53","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2016.05.004_bib54","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2016.05.004_bib55","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2016.05.004_bib56","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2016.05.004_bib57","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.beem.2016.05.004_bib58","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1007\/s00125-014-3374-x","article-title":"Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis","volume":"57","author":"Erqou","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.beem.2016.05.004_bib59","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/s00125-014-3409-3","article-title":"A\u00a0dysglycaemic effect of statins in diabetes: relevance to clinical practice?","volume":"57","author":"Swerdlow","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.beem.2016.05.004_bib60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14779072.6.4.447","article-title":"Ezetimibe: cholesterol lowering and beyond","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.beem.2016.05.004_bib61","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial","volume":"52","author":"Fleg","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2016.05.004_bib62","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib63","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/17425255.2012.672973","article-title":"Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes","volume":"8","author":"Younk","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.beem.2016.05.004_bib64","first-page":"CD009361","article-title":"Colesevelam for type 2 diabetes mellitus","volume":"12","author":"Ooi","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.beem.2016.05.004_bib65","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidaemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2016.05.004_bib66","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib67","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.clnu.2014.09.019","article-title":"Effect of niacin on lipids and glucose in patients with type 2 diabetes: a meta-analysis of randomized, controlled clinical trials","volume":"34","author":"Ding","year":"2015","journal-title":"Clin Nutr"},{"key":"10.1016\/j.beem.2016.05.004_bib68","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacl.2015.02.006","article-title":"Safety and tolerability of extended-release niacin-laropiprant: pooled analyses for 11,310 patients in 12 controlled clinical trials","volume":"9","author":"McKenney","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.beem.2016.05.004_bib69","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2010.03.017","article-title":"The ARBITER 6-HALTS trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration","volume":"55","author":"Villines","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2016.05.004_bib70","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib71","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1462-8902.2004.00325.x","article-title":"The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes","volume":"6","author":"Buse","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.beem.2016.05.004_bib73","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus","volume":"147","author":"Bolen","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2016.05.004_bib74","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1463-1326.2011.01423.x","article-title":"Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes","volume":"13","author":"Chaudhuri","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.beem.2016.05.004_bib75","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.2337\/dc06-1903","article-title":"Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidaemia","volume":"30","author":"Deeg","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2016.05.004_bib76","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12325-011-0088-z","article-title":"DPP-4 inhibitors and lipids: systematic review and meta-analysis","volume":"29","author":"Monami","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.beem.2016.05.004_bib77","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis","volume":"37","author":"Sun","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.beem.2016.05.004_bib78","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3810\/pgm.2013.05.2667","article-title":"Effects of dapagliflozin on cardiovascular risk factors","volume":"125","author":"Ptaszynska","year":"2013","journal-title":"Postgrad Med"},{"key":"10.1016\/j.beem.2016.05.004_bib79","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40265-014-0225-5","article-title":"Canagliflozin: a review of its use in patients with type 2 diabetes mellitus","volume":"74","author":"Plosker","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.beem.2016.05.004_bib80","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","article-title":"Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations","volume":"154","author":"Bennett","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2016.05.004_bib81","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3810\/pgm.2013.05.2654","article-title":"Sodium-glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus","volume":"125","author":"Guthrie","year":"2013","journal-title":"Postgrad Med"},{"key":"10.1016\/j.beem.2016.05.004_bib82","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.amjmed.2008.09.041","article-title":"Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis","volume":"122","author":"Buchwald","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib83","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jama.299.3.316","article-title":"Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial","volume":"299","author":"Dixon","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2016.05.004_bib84","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa1200225","article-title":"Bariatric surgery versus intensive medical therapy in obese patients with diabetes","volume":"366","author":"Schauer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib85","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1200111","article-title":"Bariatric surgery versus conventional medical therapy for type 2 diabetes","volume":"366","author":"Mingrone","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib86","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1001\/jama.2013.5835","article-title":"Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidaemia: the diabetes surgery study randomized clinical trial","volume":"309","author":"Ikramuddin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2016.05.004_bib87","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa1401329","article-title":"Bariatric surgery versus intensive medical therapy for diabetes\u20133-year outcomes","volume":"370","author":"Schauer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib88","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric surgery and long-term cardiovascular events","volume":"307","author":"Sjostrom","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2016.05.004_bib89","doi-asserted-by":"crossref","unstructured":"Mihaylova B, Emberson J, Blackwell L, et\u00a0al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 380: 581\u2013590.","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"10.1016\/j.beem.2016.05.004_bib90","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.beem.2016.05.004_bib91","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2016.05.004_bib92","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib93","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2016.05.004_bib94","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-med-050311-163305","article-title":"Future of cholesteryl ester transfer protein inhibitors","volume":"65","author":"Rader","year":"2014","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.beem.2016.05.004_bib95","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolaemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.beem.2016.05.004_bib96","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolaemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.beem.2016.05.004_bib97","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ecl.2014.08.008","article-title":"New therapies for reducing low-density lipoprotein cholesterol","volume":"43","author":"Stein","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.beem.2016.05.004_bib98","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/ATVBAHA.115.305492","article-title":"Human genetics of atherothrombotic disease and its risk factors","volume":"35","author":"Rader","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2016.05.004_bib99","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X16300173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X16300173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:51:27Z","timestamp":1761497487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X16300173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1521690X16300173"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2016.05.004","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing dyslipidaemia in type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2016.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}